{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:18:21Z","timestamp":1781104701750,"version":"3.54.1"},"reference-count":88,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pain Manag."],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.2217\/pmt-2023-0031","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:45:18Z","timestamp":1697618718000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Crizanlizumab in Sickle Cell Disease"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-1884","authenticated-orcid":false,"given":"Kiranveer","family":"Kaur","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, East Carolina University, Greenville, NC27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, East Carolina University, Greenville, NC27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-7887","authenticated-orcid":false,"given":"Darla","family":"Liles","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, East Carolina University, Greenville, NC27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13430"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200203000-00005"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08273-9"},{"key":"e_1_3_5_6_1","unstructured":"CDC . Data & statistics on sickle cell disease. (2022). www.cdc.gov\/ncbddd\/sicklecell\/data.htm"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02412-5"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2018.1549801"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.921.921"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111918"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.14.4428"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.3.527.527"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78941-8"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01237-z"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620713483063"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052522799"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.11.007"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10739680490278402"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(94)90037-X"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10739680490437559"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0713"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1955"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S278285"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020623"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01663-2"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X211007933"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519896437"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1728763"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.79.3.560"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80055-J"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15807"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009779"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285718"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169364"},{"key":"e_1_3_5_37_1","unstructured":"US FDA . Crizanlizumab FDA prescribing information. (2019). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761128s000lbl.pdf"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008209"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149849"},{"key":"e_1_3_5_42_1","unstructured":"US FDA . FDA approves crizanlizumab-tmca for sickle cell disease. (2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizanlizumab-tmca-sickle-cell-disease"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25308"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125868"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17739"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140428"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137434"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125775"},{"key":"e_1_3_5_49_1","unstructured":"www.novartis.com\/news\/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157004"},{"key":"e_1_3_5_51_1","unstructured":"ASH clinical news . Crizanlizumab-tmca becomes first approved targeted therapy for sickle cell disease.(2021)."},{"key":"e_1_3_5_52_1","unstructured":"ClinicalTrials.gov . Study of crizanlizumab for prevention of silent cerebral infarcts in SCA (CRIZ). (2023). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05334576"},{"key":"e_1_3_5_53_1","first-page":"PB2512","article-title":"Safety of crizanlizumab in patients with sickle cell disease: integrated post-marketing surveillance analysis","volume":"387608","author":"Abboud M","year":"2023","unstructured":"Abboud M , KanterJ , MarfoKet al. Safety of crizanlizumab in patients with sickle cell disease: integrated post-marketing surveillance analysis. EHA Libr.387608, PB2512 (2023).","journal-title":"EHA Libr."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000821400.77896.85"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152362"},{"key":"e_1_3_5_56_1","unstructured":"Terry M . FDA approves Novartis\u2019 Adakveo for pain events associated with sickle cell disease. (2019). www.biospace.com\/article\/fda-approves-novartis-adakveo-for-sickle-cell-disease"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.429"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.1787"},{"key":"e_1_3_5_59_1","unstructured":"ASH Clinical News webpage . ICER report finds that sickle cell drugs are too expensive. (2020). https:\/\/ashpublications.org\/ashclinicalnews\/news\/4947\/ICER-Report-Finds-That-Sickle-Cell-Drugs-Are-Too"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03499-4"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029621999099"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218234"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000194"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317803"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.09.013"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006000"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01401-6"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa623"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050354"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30216-7"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.014"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30215-5"},{"issue":"5","key":"e_1_3_5_73_1","first-page":"268","article-title":"Association between D-dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis","volume":"45","author":"Sakka M","year":"2020","unstructured":"Sakka M , ConnorsJM , H\u00e9kimianGet al. Association between D-dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. J. Med. Vasc.45(5), 268\u2013274 (2020).","journal-title":"J. Med. Vasc."},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.053311"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.314872"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25482"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2014.12.001"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.09.013"},{"key":"e_1_3_5_79_1","unstructured":"American College of Clinical Pharmacology . FDA approves Adakveo for vasoocclusive crises in patients with sickle cell disease. (2019). https:\/\/accp1.org\/Members\/ACCP1\/5Publications_and_News\/FDA-Approves-ADAKVEO-Vasoocclusive-Crises-Sickle-Cell-Disease.aspx"},{"key":"e_1_3_5_80_1","unstructured":"EMA . Adakveo. (2023). www.ema.europa.eu\/en\/medicines\/human\/referrals\/adakveo"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133896"},{"key":"e_1_3_5_82_1","unstructured":"ClinicalTrials.gov . Platform study of novel ruxolitinib combinations in myelofibrosis patients (ADORE). (2023). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04097821"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78941-8"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.378"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01237-z"},{"key":"e_1_3_5_86_1","unstructured":"National Heart Lung and Blood Institute . A century of progress: milestones in sickle cell disease research and care. (2010). www.nhlbi.nih.gov\/new\/sicklecell.htm"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30154-1"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000250"},{"key":"e_1_3_5_89_1","unstructured":"ClinicalTrials.gov . Gene correction in autologous CD34+ hematopoietic stem cells (HbS to HbA) to treat severe sickle cell disease. (2023 ). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04819841"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.03.010"}],"container-title":["Pain Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pmt-2023-0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:23:35Z","timestamp":1715984615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pmt-2023-0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.2217\/pmt-2023-0031"],"URL":"https:\/\/doi.org\/10.2217\/pmt-2023-0031","relation":{},"ISSN":["1758-1869","1758-1877"],"issn-type":[{"value":"1758-1869","type":"print"},{"value":"1758-1877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}